Dianthus Therapeutics Prices $625M Public Offering at $81.00 Per Share, Extending Cash Runway

summarizeSummary

Dianthus Therapeutics finalized its public offering, raising approximately $587.5 million at $81.00 per share, which will significantly extend its cash runway but also result in substantial shareholder dilution.

check_boxKey Events

• Offering Priced

  Finalizes the terms and pricing of the public offering, selling 7,313,582 shares of common stock and pre-funded warrants for 402,468 shares, initiated on March 9, 2026.

• Significant Capital Raise

  The offering is expected to generate approximately $587.5 million in net proceeds, potentially increasing to $673.5 million if the underwriters' option to purchase additional shares is fully exercised.

• Pricing Details

  Shares were priced at $81.00, a discount to the last reported sale price of $86.92 on March 10, 2026, but the offering occurs while the stock is trading near its 52-week high.

• Extended Cash Runway

  Proceeds are earmarked for clinical and preclinical development, commercial readiness, and general corporate purposes, projected to fund operations into 2030.

auto_awesomeAnalysis

This 424B5 filing officially prices a significant public offering of common stock and pre-funded warrants, raising approximately $587.5 million in net proceeds (or $673.5 million if the underwriters' option is fully exercised). The offering, priced at $81.00 per share, represents a discount to the last reported sale price of $86.92 on March 10, 2026, but occurs while the stock is trading near its 52-week high. This substantial capital raise, following the positive "GO decision" in the Phase 3 CAPTIVATE trial, is intended to fund clinical and preclinical development, commercial readiness, and general corporate purposes, extending the company's cash runway into 2030. While the offering provides critical funding for a clinical-stage biotech, the issuance of 7.7 million to 8.9 million new shares (including warrants) represents significant potential dilution of 17.85% to 20.53% to existing shareholders.